Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Asia Pacific Generic Injectables Market Size

The Asia Pacific generic injectables market was valued at USD 7.5 billion in 2023, driven by the increasing investment in the generic injectables sector and the rising healthcare needs. The market is expected to grow at a CAGR of 8.30% during the forecast period of 2024-2032, with the values likely to rise from USD 8.1 billion in 2024 to USD 15.3 billion by 2032. 

Asia Pacific Generic Injectables Market Outlook

  • Increased regulatory support leading to faster approvals of first-time generics and favorable government policies encouraging the uptake of generic injectables are influencing the market share significantly.
  • In June 2023, RK Pharma Inc., received an investment of USD 200 million from a leading Asia-Pacific-based investment firm PAG to strengthen its position as a leading specialty injectable pharmaceutical company. Such substantial investment initiatives in the generic medication sector are likely to elevate the Asia Pacific generic injectables market value.
  • Recent data reveals that Asia accounts for an alarming 45% of all global breast cancer cases and almost 58% of cervical cancer associated mortality globally. This surge in the burden of cancer and other chronic diseases is poised to fuel the demand for cost-effective healthcare solutions including generic injectables.

Asia Pacific Generic Injectables Market Analysis

Generic injectables offer less expensive alternatives to branded medications with similar efficacy and safety profile. Compared to oral drugs, generic injectables are administered intravenously or intramuscularly, providing a faster therapeutic effect as they enter the bloodstream directly, resulting in quicker absorption and rapid onset of action. Factors such as shorter and cheaper research and development (R&D) cycles along with faster approvals of generic medications are influencing the global generic injectables market landscape. Besides increased regulatory support and favorable government policies encouraging the use of generics to reduce healthcare costs, the rising innovations in drug delivery systems such as advanced formulations and prefilled syringes are a significant driver of the Asia Pacific generic injectables market growth.

The market is witnessing increased demand for more affordable treatment options, including generic injectables, owing to the rise in chronic health issues in the Asia Pacific region. Recent data reveals that Asia accounts for an alarming 45% of all global breast cancer cases and almost 58% of cervical cancer mortality globally, with the cases of both cancers projected to rise in the Asia Pacific countries faster than the rest of the world. This surge in the burden of cancer and other chronic diseases is poised to augment the demand for cost-effective healthcare solutions, thereby fuelling the Asia Pacific generic injectables market demand.

One of the major market trends is the rising investments in the generic injectables sector. For instance, in June 2023, RK Pharma Inc., a generic pharmaceutical company specializing in complex injectables received an investment of USD 200 million from a leading Asia-Pacific-based investment firm PAG. The investment was intended to accelerate its growth plans and develop further innovative medicines, as well as strengthen its position as a leading fully vertically integrated specialty injectable pharmaceutical company. Such substantial investment initiatives are likely to boost the market share for new and advanced generic injectables.

Asia Pacific Generic Injectables Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Market Breakup Categories
Product Type Large Molecule Injectables (Monoclonal Antibodies (mAbs), Insulin, Others), Small Molecule Injectables
Container Type Vials, Premix, Prefilled Syringes, Ampoules, Others
Application Oncology, Cardiovascular, CNS, Infectious Diseases, Autoimmune Disorders, Others
Route of Administration     Intravenous, Intramuscular, Subcutaneous, Others
Distribution Channel Hospital, Retail Pharmacy, Others
Country China, Japan, India, ASEAN, Australia, Others 

Leading Players in the Asia Pacific Generic Injectables Market 

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Pfizer Inc.

The global pharmaceutical giant Pfizer has a strong presence in the market through its subsidiary, Hospira (acquired in 2015) which specializes in injectable drugs and infusion technologies.

Baxter

Baxter International Inc. is a global leader in generic injectables, primarily serving areas such as anesthesia and critical care. It is actively involved in strategic partnerships to accelerate the development of generic injectables in various therapeutic categories.

Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation, via its spin-off Sandoz, acts as a leading player in the generic injectables market, particularly manufacturing generic products in various therapeutic categories including oncology, immunology, and endocrinology.

Fresenius SE & Co. KGaA

The company specializes in the production of high-quality, cost-effective injectables for use in hospitals and outpatient care in therapeutic areas such as anesthesia, oncology, critical care, and anti-infectives.

Other key players in the market include Endo, Inc., Dr. Reddy’s Laboratories Ltd., Viatris Inc., Biocon, Sanofi, Lupin, Aurobindo Pharma Limited, and Sun Pharmaceutical Industries Ltd.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product Type
  • Container Type
  • Application
  • Route of Administration
  • Distribution Channel
  • Region
Breakup by Product Type
  • Large Molecule Injectables
  • Small Molecule Injectables
Breakup by Container Type
  • Vials
  • Premix
  • Prefilled Syringes
  • Ampoules
  • Others
Breakup by Application
  • Oncology
  • Cardiovascular
  • CNS
  • Infectious Diseases
  • Autoimmune Disorders
  • Others
Breakup by Route of Administration
  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others
Breakup by Region
  • China 
  • Japan
  • India
  • ASEAN 
  • Australia
  • Others
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Pfizer Inc.
  • Baxter
  • Novartis Pharmaceuticals Corporation
  • Fresenius SE & Co. KGaA
  • Endo, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Viatris Inc.
  • Biocon
  • Sanofi
  • Lupin.
  • Aurobindo Pharma Limited
  • Sun Pharmaceutical Industries Ltd.  

Asia Pacific Generic Injectables Market Report Snapshots

Asia Pacific Generic Injectables Market Size

Asia Pacific Generic Injectables Market Analysis

Asia Pacific Generic Injectables Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market attained a value of about USD 7.5 billion in 2023 driven by the rising prevalence of chronic diseases in the region.

The market is anticipated to grow at a CAGR of 8.30% during the forecast period of 2024-2032, likely to reach a market value of USD 15.3 billion by 2032.

The growing geriatric population and increasing innovations in drug delivery systems are fuelling the demand for the market.

One of the significant trends in the market is increasing investment in the generic injectables sector. In June 2023, RK Pharma Inc., received an investment of USD 200 million from a leading Asia-Pacific-based investment firm to strengthen its position as a leading specialty injectable pharmaceutical company.

Based on the product type, the market is broadly segmented into large molecule injectables and small molecule injectables. Large molecule injectables are further divided into monoclonal antibodies (mAbs), and insulin, among others.

Container types available in the market include vials, premix, prefilled syringes, and ampoules, among others.

Major applications of the generic injectables include oncology, cardiovascular, CNS, infectious diseases, and autoimmune disorders, among others.

The market breakup by route of administration includes intravenous, intramuscular, and subcutaneous, among others.

Distribution channels of the market are hospitals and retail pharmacies, among others.

The market segmentation by countries includes China, Japan, India, ASEAN, and Australia, among others. 

The key players in the market are Pfizer Inc., Baxter, Novartis Pharmaceuticals Corporation, Fresenius SE & Co. KGaA, Endo, Inc., Dr. Reddy’s Laboratories Ltd., Viatris Inc., Biocon, Sanofi, Lupin, Aurobindo Pharma Limited, and Sun Pharmaceutical Industries Ltd.

Purchase Full Report

Datasheet

 

USD 2,639

USD 2,399

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 4,399

USD 3,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 5,829

USD 5,299

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 6,929

USD 6,299

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124